BioTie Therapies (Finland) announce new partnership with Tripos (USA)
Feb. 7, 2005–Tripos, Inc., (USA) a leading provider of drug discovery chemistry and informatics products and services, and BioTie Therapies Corp., a Finnish biotech company, have announced a partnership to enhance BioTie’s drug discovery efforts, which include innovative medicines for the treatment of dependence disorders, inflammatory diseases and thrombosis.
Under the agreement, Tripos will identify and optimize backup series for one of BioTie’s key drug discovery programs. Tripos’ LeadHopping(TM) technology is essential to identifying structurally distinct, though shape-similar, compounds whose chemistry is unrelated to that of the original lead and therefore free of patent restrictions. Tripos will then rapidly create compound libraries for in-house screening by BioTie.
BioTie Therapies Corp. is a public Finnish biotech company specializing in pharmaceutical product development. Its main focus is on products for the treatment of dependence disorders, inflammatory diseases and thrombosis. For more information, please visit http://www.biotie.com.
News Source: Business Wire 2005
10 January 2023
Workshop #3: Reducing Pharmaceutical Residuals in the Baltic Sea Region – Comparative Analysis and Assessment of Possibilities | 9 February at 11:00-15:05 EET
4 January 2023
EDAH - a new European project ahead